262 related articles for article (PubMed ID: 33512430)
1. Syndecan-1 and stromal heparan sulfate proteoglycans: key moderators of plasma cell biology and myeloma pathogenesis.
Ren Z; Spaargaren M; Pals ST
Blood; 2021 Apr; 137(13):1713-1718. PubMed ID: 33512430
[TBL] [Abstract][Full Text] [Related]
2. Syndecan-1: a dynamic regulator of the myeloma microenvironment.
Sanderson RD; Yang Y
Clin Exp Metastasis; 2008; 25(2):149-59. PubMed ID: 18027090
[TBL] [Abstract][Full Text] [Related]
3. Heparan sulfate proteoglycans in the control of B cell development and the pathogenesis of multiple myeloma.
Reijmers RM; Spaargaren M; Pals ST
FEBS J; 2013 May; 280(10):2180-93. PubMed ID: 23419151
[TBL] [Abstract][Full Text] [Related]
4. The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy.
Yang Y; MacLeod V; Dai Y; Khotskaya-Sample Y; Shriver Z; Venkataraman G; Sasisekharan R; Naggi A; Torri G; Casu B; Vlodavsky I; Suva LJ; Epstein J; Yaccoby S; Shaughnessy JD; Barlogie B; Sanderson RD
Blood; 2007 Sep; 110(6):2041-8. PubMed ID: 17536013
[TBL] [Abstract][Full Text] [Related]
5. The CXCL12gamma chemokine immobilized by heparan sulfate on stromal niche cells controls adhesion and mediates drug resistance in multiple myeloma.
Ren Z; Lantermans H; Kuil A; Kraan W; Arenzana-Seisdedos F; Kersten MJ; Spaargaren M; Pals ST
J Hematol Oncol; 2021 Jan; 14(1):11. PubMed ID: 33436043
[TBL] [Abstract][Full Text] [Related]
6. Haematologists usually over-estimate the percentage of CD138+ plasma cells in marrow biopsies.
Chai KY; Boyke Berahmana AA; Morison IM
Pathology; 2019 Oct; 51(6):647-648. PubMed ID: 31470997
[No Abstract] [Full Text] [Related]
7. Shed syndecan-1 translocates to the nucleus of cells delivering growth factors and inhibiting histone acetylation: a novel mechanism of tumor-host cross-talk.
Stewart MD; Ramani VC; Sanderson RD
J Biol Chem; 2015 Jan; 290(2):941-9. PubMed ID: 25404732
[TBL] [Abstract][Full Text] [Related]
8. Syndecan-1 promotes Wnt/β-catenin signaling in multiple myeloma by presenting Wnts and R-spondins.
Ren Z; van Andel H; de Lau W; Hartholt RB; Maurice MM; Clevers H; Kersten MJ; Spaargaren M; Pals ST
Blood; 2018 Mar; 131(9):982-994. PubMed ID: 29212806
[TBL] [Abstract][Full Text] [Related]
9. Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma.
Mahtouk K; Cremer FW; Rème T; Jourdan M; Baudard M; Moreaux J; Requirand G; Fiol G; De Vos J; Moos M; Quittet P; Goldschmidt H; Rossi JF; Hose D; Klein B
Oncogene; 2006 Nov; 25(54):7180-91. PubMed ID: 16732320
[TBL] [Abstract][Full Text] [Related]
10. CD138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies.
Chilosi M; Adami F; Lestani M; Montagna L; Cimarosto L; Semenzato G; Pizzolo G; Menestrina F
Mod Pathol; 1999 Dec; 12(12):1101-6. PubMed ID: 10619261
[TBL] [Abstract][Full Text] [Related]
11. Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma.
Derksen PW; Keehnen RM; Evers LM; van Oers MH; Spaargaren M; Pals ST
Blood; 2002 Feb; 99(4):1405-10. PubMed ID: 11830493
[TBL] [Abstract][Full Text] [Related]
12. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions.
Bayer-Garner IB; Sanderson RD; Dhodapkar MV; Owens RB; Wilson CS
Mod Pathol; 2001 Oct; 14(10):1052-8. PubMed ID: 11598177
[TBL] [Abstract][Full Text] [Related]
13. Membrane-anchored proteoglycans of mouse macrophages: P388D1 cells express a syndecan-4-like heparan sulfate proteoglycan and a distinct chondroitin sulfate form.
Yeaman C; Rapraeger AC
J Cell Physiol; 1993 Nov; 157(2):413-25. PubMed ID: 8227171
[TBL] [Abstract][Full Text] [Related]
14. Targeting EXT1 reveals a crucial role for heparan sulfate in the growth of multiple myeloma.
Reijmers RM; Groen RW; Rozemuller H; Kuil A; de Haan-Kramer A; Csikós T; Martens AC; Spaargaren M; Pals ST
Blood; 2010 Jan; 115(3):601-4. PubMed ID: 19965677
[TBL] [Abstract][Full Text] [Related]
15. Bone marrow stromal cell interaction reduces syndecan-1 expression and induces kinomic changes in myeloma cells.
Fuhler GM; Baanstra M; Chesik D; Somasundaram R; Seckinger A; Hose D; Peppelenbosch MP; Bos NA
Exp Cell Res; 2010 Jul; 316(11):1816-28. PubMed ID: 20307537
[TBL] [Abstract][Full Text] [Related]
16. Heparan sulfate proteoglycan expression in chronic cholestatic human liver diseases.
Roskams T; Rosenbaum J; De Vos R; David G; Desmet V
Hepatology; 1996 Sep; 24(3):524-32. PubMed ID: 8781318
[TBL] [Abstract][Full Text] [Related]
17. Syndecan-1 (CD138), Carcinomas and EMT.
Couchman JR
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921767
[TBL] [Abstract][Full Text] [Related]
18. Quantification of bone marrow plasma cell infiltration in multiple myeloma: usefulness of bone marrow aspirate clot with CD138 immunohistochemistry.
Matsue K; Matsue Y; Kumata K; Usui Y; Suehara Y; Fukumoto K; Fujisawa M; Narita K; Takeuchi M
Hematol Oncol; 2017 Sep; 35(3):323-328. PubMed ID: 27140172
[TBL] [Abstract][Full Text] [Related]
19. 3-O sulfation of syndecan-1 mediated by the sulfotransferase HS3ST3a1 enhances myeloma aggressiveness.
Baert L; Manfroi B; Quintero M; Chavarria O; Barbon PV; Clement E; Zeller A; Van Kuppevelt T; Sturm N; Moreaux J; Tveita A; Bogen B; McKee T; Huard B
Matrix Biol; 2023 Jun; 120():60-75. PubMed ID: 37201729
[TBL] [Abstract][Full Text] [Related]
20. Soluble syndecan-1 promotes growth of myeloma tumors in vivo.
Yang Y; Yaccoby S; Liu W; Langford JK; Pumphrey CY; Theus A; Epstein J; Sanderson RD
Blood; 2002 Jul; 100(2):610-7. PubMed ID: 12091355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
